Gelonghui 29 April, Cornerstone Pharmaceutical Industry-B (02616)Pokerrankings.HK) announcementPokerrankingsThe company was informed by the chief executive officer, president of research and development and executive director yang Jianxin that it had purchased a total of 3.345 million shares on the open market with its own funds during the period of about six months prior to the date of the announcement Since Yang Jianxin became CEO in August 2022, he has bought a total of 7. 5%.PokerrankingsThe purchase price ranges from HK $0.82 to HK $4.60 for 529500 shares. After the share purchase, Yang Jianxin held a total of equivalent to the company at the date of the announcement.PokerrankingsShares with a total issued share capital of about 4.97%.

Yang Jianxin told the company that it is full of confidence in the future of the company, and that increasing its stake in the company represents his belief in the company's ability to achieve rapid growth while maintaining steady operation in a complex and changeable market environment, as well as unremitting support for the company's growth and development. Yang Jianxin does not rule out the possibility that he may further increase his stake in the company in due course.

The board of directors believes that the increase of the company's shares by its CEO, president of R & D and executive director reflects Yang Jianxin's long-term commitment to the company and full confidence in the company's future business prospects.